What people don’t know is that I consulted to the company that developed and manufactured the AstraZeneca adenovirus ‘vaccine’, Oxford Biomedica, in 2013. Then, they were developing and manufacturing their lentiviral vector gene therapy product for Novartis, Kymriah, approved by FDA August 2017. It has a warning on the label on neurological toxicities and Cytokine Release Syndrome.
A research body connected with UKs Office for Life Sciences paid me a small fee to find a company (Oxford Biomedica) and consult to them, which resulted in Oxford Biomedica gaining a $9 million Government Grant for the Advanced Manufacturing Supply Chain initiative. The Office for Life Sciences got quite excited
Keep reading with a 7-day free trial
Subscribe to INSIDE PHARMA to keep reading this post and get 7 days of free access to the full post archives.